Research programme: HIV ribozyme therapy - Viratis
Latest Information Update: 11 May 2010
At a glance
- Originator Viratis
- Mechanism of Action CCR5 receptor antagonists; CXCR4 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 06 Jun 2007 Preclinical trials in HIV infections in United Kingdom (IV)